Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats

Hypertension Research

Volumn 27, Issue 4, 2004, Pages 293-299

  Okada, Kenta ^a   Hirano, Tsutomu ^a   Ran, Jianmin ^a   Adachi, Mitsuru ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fructose fed rat; Insulin resistance; Olmesartan medoxomil; Triglyceride metabolism

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; FATTY ACID; FRUCTOSE; GLUCOSE; INSULIN; LIPOPROTEIN LIPASE; OLMESARTAN; TRIACYLGLYCEROL; TYLOXAPOL;

ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FATTY ACID BLOOD LEVEL; GLUCOSE METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOGENESIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; FATTY ACIDS, NONESTERIFIED; FRUCTOSE; GLUCOSE TOLERANCE TEST; HEART RATE; IMIDAZOLES; INSULIN; INSULIN RESISTANCE; LIPOPROTEIN LIPASE; MALE; RATS; RATS, WISTAR; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TRIGLYCERIDES;

EID: 2342644068     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.27.293     Document Type: Article

References (33)

1. Julius S: Hemodynamic and neurohumoral evidence of multifaceted pathophysiology in human hypertension. J Cardiovasc Pharmacol 1990; 15(Suppl 5): S53-S58.
2. Rao RH: Pressor dose of angiotensin II increase hepatic glucose output and decrease insulin sensitivity in rats. J Endocrinol 1996; 148: 311-318.
3. Richey JM, Ader M, Moore D, et al: Angiotensin II induces insulin resistance independent of changes in interstitial insulin. Am J Physiol 1999; 277: E920-E926.
4. Ogihara T, Asano T, Ando K, et al: Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002; 40: 872-879.
5. Iimura O, Shimamoto K, Matsuda K, et al: Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens 1995; 8: 353-357.
6. Frossard M, Joukhadar C, Steffen G, et al: Paracrine effects of angiotensin-converting-enzyme and angiotensin-II-receptor-inhibitor on transcapillary glucose transport in humans. Life Sci 2000; 66: 147-154.
7. Jeppesen J, Hollenbeck CB, Zhou MY, et al: Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity, and postprandial lipemia. Arterioscler Thromb Vasc Biol 1995; 15: 320-324.
8. Kobayashi N, Fujimori I, Watanabe M, et al: Real-time monitoring of metabolic reactions by microdialysis in combination with tandem mass spectrometry: hydrolysis of CS-866 in vitro in human and rat plasma, livers, and small intestines. Anal Biochem 2000; 15: 272-278.
9. Hirano T, Mamo JC, Furukawa S, et al: Effect of acute hyperglycemia on plasma triglyceride concentration and triglyceride secretion rate in non-fasted rats. Diabetes Res Clin Pract 1990; 9: 231-238.
10. Kobayashi J, Hashimoto H, Fukamachi I, et al: Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin Chim Acta 1993; 216: 113-123.
11. Bergman RN: Lilly lecture 1989: toward physiological understanding of glucose tolerance: minimal-model approach. Diabetes 1989; 38: 1512-1527.
12. Lithell HO, Anderson PE: Antihypertensive treatment in insulin resistant patients. Hypertens Res 1996; 19(Suppl): S75-S79.
13. Uehara M, Kishikawa H, Isami S, et al: Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans. Diabetologia 1994; 37: 300-307.
14. Moan A, Hoieggen A, Seljeflot I, et al: The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 1996; 14: 1093-1097.
15. Laakso M, Karjalainen L, Lempiainen-Kuosa P: Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 1996; 28: 392-396.
16. Lerch M, Teuscher AU, Beissner P, et al: Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents. J Cardiovasc Pharmacol 1998; 31: 576-580.
17. Paolisso G, Tagliamonte MR, Gambardella A, et al: Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens 1997; 11: 307-312.
18. Higashiura K, Ura N, Takada T, et al: The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens 2000; 13: 290-297.
19. Umeda M, Kanda T, Murakami M: Effects of angiotensin II receptor antagonists on insulin resistance syndrome and leptin in sucrose-fed spontaneously hypertensive rats. Hypertens Res 2003; 26: 485-492.
20. Henriksen EJ, Jacob S, Kinnick TR, et al: Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001; 38: 884-890.
21. Mizuno M, Sada T, Kato M, et al: Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens Res 2002; 25: 271-278.
22. Koike H, Sada T, Mizuno M: In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens 2001; 19(Suppl 1): S3-S14.
23. Togashi N, Ura N, Higashiura K, et al: The contribution of skeletal muscle tumor necrosis factor-α to insulin resistance and hypertension in fructose-fed rats. J Hypertens 2000; 18: 1605-1610.
24. Kamide K, Rakugi H, Higaki J, et al: The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats. Am J Hypertens 2002; 15: 66-71.
25. Hirano T, Mamo JC, Poapst ME, et al: Very-low-density lipoprotein triglyceride kinetics in acute and chronic carbohydrate-fed rats. Am J Physiol 1988; 255: 236-240.
26. Hirano T, Mamo JC, Poapst ME, et al: Impaired very low-density lipoprotein-triglyceride catabolism in acute and chronic fructose-fed rats. Am J Physiol 1989; 256: 559-565.
27. Park OJ, Cesar D, Faix D, et al: Mechanisms of fructose-induced hypertriglyceridaemia in the rat: activation of hepatic pyruvate dehydrogenase through inhibition of pyruvate dehydrogenase kinase. Biochem J 1992; 282: 753-757.
28. Sparks JD, Sparks CE: Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta 1994; 1215: 9-32.
29. Chirieac DV, Chirieac LR, Corsetti JP, et al: Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production. Am J Physiol Endocrinol Metab 2000; 279: 1003-1011.
30. Mead JR, Irvine SA, Ramji DP: Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med 2002; 80: 753-769.
31. Mamo JC, Hirano T, James L, et al: Partial characterization of the fructose-induced defect in very-low-density lipoprotein triglyceride metabolism. Metabolism 1991; 40: 888-893.
32. Naka Y, Yoshino G, Hirano T, et al: Triglyceride metabolism in heterozygote of Watanabe heritable hyperlipidemic rabbit. Atherosclerosis 1998; 136: 325-332.
33. Kim JI, Tsujino T, Fujioka Y, Saito K, Yokoyama M: Bezafibrate improves hypertension and insulin sensitivity in humans. Hypertens Res 2003 26: 307-313.